Cianergoline
 | |
| Clinical data | |
|---|---|
| Other names | 355/1057; 6-Methyl-8β-(2-cyano)propionamidoergoline; 2-Cyano-3-(6-methylergolin-8β-yl)propionamide; 2-CMEBP |
| Drug class | Dopamine receptor agonist; Antihypertensive agent |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H22N4O |
| Molar mass | 322.412 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cianergoline (INN), also known as 355/1057 or as 2-cyano-3-(6-methylergolin-8β-yl)propionamide (2-CMEBP), is a dopamine receptor agonist described as an antihypertensive agent of the ergoline family which was never marketed.[1][2][3] It has atypical properties as a dopamine receptor agonist compared to other ergolines, for instance having less central activity and showing predominant cardiovascular effects.[3] In addition to its dopamine receptor agonism, cianergoline may interact with α-adrenergic receptors, which may or may not also be involved in its antihypertensive effects.[3][4][5] The drug was first described in the scientific literature by 1983.[1][6][2] It was studied for treatment of essential hypertension.[3]
See also
[edit]References
[edit]- 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 6 May 2026.
- 1 2 Riva, F., & Sardi, A. (1984). Cianergoline. Drugs of the Future, 9, 13. https://scholar.google.com/scholar?cluster=14938482905837820153
- 1 2 3 4 Bise G, Foletti C, Beretta-Piccoli C, Weidmann P, Ziegler WH, Mordasini R, et al. (1985). "Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension". European Journal of Clinical Pharmacology. 29 (1): 25–31. doi:10.1007/BF00547364. PMID 4054204.
- ↑ Potter DE, Shumate DJ (1987). "Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function". Journal of Ocular Pharmacology. 3 (4): 309–321. doi:10.1089/jop.1987.3.309. PMID 3503920.
- ↑ Salvati P, Bianchi G (April 1985). "Involvement of peripheral dopamine receptors in the antihypertensive effect of a new ergoline derivative (355/1057)". Archives Internationales de Pharmacodynamie et de Therapie. 274 (2): 291–304. PMID 4026460.
- ↑ Salvati P, Caravaggi AM, Lamberti E, Monteggia M, Bianchi G (1983). "Cardiovascular effects of a new antihypertensive agent in several species". Arzneimittel-Forschung. 33 (8): 1098–1106. PMID 6685486.
 | This antihypertensive-related article is a stub. You can help Wikipedia by adding missing information. |
